ERBB2 and breast carcinoma: Previous studies have identified FOXA1 as a mediator of transcriptional responses to HER2-targeted therapy in breast cancer, with the ability of FOXA1 protein to bind to the HER2 gene promoter and influence its transcription26, 27.